Systematic Genetic Study of Diabetic Youth in a Single Country Reveals the Prevalence of Diabetes Subtypes, Novel Candidate Genes, and Response to Precision Therapy.

Clicks: 425
ID: 97441
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #4 of 50 articles by views in Diabetes

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Identifying gene variants causing monogenic diabetes increases understanding of disease etiology and allows for implementation of precision therapy to improve metabolic control and quality of life. Here, we aimed to assess the prevalence of monogenic diabetes in diabetic youth in Lithuania, uncover potential diabetes-related gene variants, and prospectively introduce precision treatment. First, we assessed all pediatric and most young adult diabetic patients in Lithuania ( = 1209) for diabetes-related autoimmune antibodies. We then screened all antibody-negative patients using targeted high-throughput sequencing of more than 300 potential candidate genes. In this group, 40.7% had monogenic diabetes, with the highest percentage (100%) in infants (diagnosis at ages 0-12 months), followed by those diagnosed at ages >1-18 years (40.3%) and at >18-25 years (22.2%). The overall prevalence of monogenic diabetes in diabetic youth in Lithuania was 3.5% (1.9% for diabetes, 0.7% for , 0.2% for and , 0.3% for , and 0.1% for ) Furthermore, we identified likely pathogenic variants in 11 additional genes. Microvascular complications were present in 26% of those with monogenic diabetes. Prospective treatment change was successful in over 50% of eligible candidates, with C-peptide over 252 pmol/L emerging as the best prognostic factor.
Reference Key
stankute2020systematicdiabetes Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Stankute, Ingrida;Verkauskiene, Rasa;Blouin, Jean-Louis;Klee, Philippe;Dobrovolskiene, Rimante;Danyte, Evalda;Dirlewanger, Mirjam;Santoni, Federico;Razanskaite-Virbickiene, Dovile;Marciulionyte, Dale;Jasinskiene, Edita;Mockeviciene, Giedre;Schwitzgebel, Valerie M;
Journal Diabetes
Year 2020
DOI
db190974
URL
Keywords
prevalence sca10 latin america and the caribbean spinocerebellar ataxia machado-joseph disease founder effects mjd sca2 sca3 sca7 spinocerebellar ataxia type 10 spinocerebellar ataxia type 2 spinocerebellar ataxia type 3 spinocerebellar ataxia type 7

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.